- AIG, Ex-CEO Greenberg Reach Pact to Settle Disputes
- Bank of America CEO Search May Extend Into 2010
- 'Cancer of Fraud' Permeates Health Care System: Critics
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Judge Erases Couple's $525,000 Mortgage Payment
- For Many in US, It Will Be a Scaled-Down Holiday Season
- Where Do Pardoned Turkeys Go?
- Jobless Claims Below 500,000, Durable Orders Slip
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- S&P Stocks Trading at New 52-Week Highs
MOST SHARED
- Garlic Price Rises Surpass Gold, Stocks in China
- Ritz-Carlton ?Struggling? in the US: President
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- S&P Stocks Trading at New 52-Week Highs
- The Executive Job Search
- Judge Erases Couple's $525,000 Mortgage Payment
- US Plans to Reduce Emissions By 17% Within Next Ten Years
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Where Do Pardoned Turkeys Go?
Text Size 
NEW YORK, Nov 2 (Reuters) - Dendreon Corp has completed its U.S. regulatory submission for its closely watched experimental prostate cancer vaccine, the company said on Monday, sending shares higher. Dendreon previously said it expected to seek U.S. approval for Provenge in November and that it expected regulators to respond by mid-2010. If approved, Provenge would be the first "therapeutic" cancer vaccine.
While conventional vaccines prevent disease, Provenge treats the condition. "With the (application) submission complete, we have taken an important step towards reaching our goal of bringing a new therapy to men with advanced prostate cancer," Dendreon Chief Executive Mitchell Gold said in a statement. Dendreon shares, which have soared 10-fold since March, were up 4.8 percent at $26.48 in premarket trading. (Reporting by Lewis Krauskopf, editing by Gerald E. McCormick) Keywords: DENDREON/ (lewis.krauskopf@thomsonreuters.com; 646-223-6082;Reuters Messaging:Lewis.Krauskopf.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
- How can you get out of debt and back on the road to recovery? Follow these ten steps.
Data is a real-time snapshot *Data is delayed at least 15 minutes